Healthcare Administrative Automation
C

Cadence Suite

Cadence Suite is ConcertAI's commercialization software for specialty pharmaceutical brands, built to show where patients stall between a prescription and steady therapy. ConcertAI launched it on April 21, 2026, at Asembia's AXS26 summit, drawing on more than 30 years of specialty pharmacy data work across 80+ specialty products. The suite joins specialty pharmacy feeds, claims, hub, support program and social determinants data so a team can tell a coverage block from a delayed fill, a lapse in therapy or a stock problem.

Workbenches are organized by team. Market Access and Patient Access cover benefits checks, prior authorization, appeals, affordability, first fill rescue, policy and formulary surveillance and payer pull through. Patient Compass turns pharmacy feeds into near real time fulfillment and persistence dashboards, and Market Intelligence adds an AI copilot for tracing the causes of fill rate and adherence trends. Field AI Assistant ranks patients for field reimbursement follow up and suggests next steps, Inventory AI Assistant warns trade teams of stockouts, and Specialty Pharmacy Benchmarking compares fill rates, abandonment and time to fill across a brand's pharmacies. Cadence Vantage and Cadence Brand Insight serve portfolio and targeting decisions.

ConcertAI's Cara platform runs the predictive alerts and data quality checks, which the company says cut data errors by up to 25%. Jazz Pharmaceuticals' reimbursement team is the named customer, and implementation can take as little as 30 days.

AI Health Index verifiedNovember 19, 2026
Compare Cadence Suite with other vendors
Founded
—
Headquarters
Cambridge, Massachusetts
Categories
healthcare-admin-automation
Indexed Products
Cadence Market Access, Cadence Patient Access, Patient Compass, Market Intelligence, Field AI Assistant, Inventory AI Assistant, Specialty Pharmacy Benchmarking, Cadence Vantage, Cadence Brand Insight
Buyer Segments
Pharmaceutical market access teams, Field reimbursement teams, Specialty brand teams, Trade and distribution teams
Assessment

Capability Axes

An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read

AI Capability
BB on AI CentralityThe model is the engine of a core module. The platform carries other value, but this capability does not exist without it.
Vendor Published

Risk signals from Cara's models decide which patients a field team calls first, which pharmacies need attention and which products face a stockout, and the copilot in Market Intelligence answers root cause questions about fill and adherence trends. Remove them and the suite still has value as a data product: connected specialty pharmacy, hub and claims feeds, fulfillment dashboards, standardized reports, case management and pharmacy benchmarking all work on aggregated data.

ConcertAI built the suite on 30 years of pharmacy data work before adding AI. The prediction layer is the engine of the prioritization and alerting modules, inside a platform whose reporting stands on its own.

BB on Autonomy and Oversight ModelThe oversight structure is described and one part is missing, commonly the threshold at which the system stops or what happens after it is wrong.
Vendor Published

Predictive alerts flag patients whose therapy start or persistence is at risk, pharmacies with backlogs and products at risk of stockout, and Field AI Assistant turns those drivers into ranked cases with next best steps. Staff then do the work: field reimbursement teams triage the case, chase the prior authorization, appeal or affordability problem and coordinate with the prescriber, and Jazz Pharmaceuticals describes its team acting on alerts to get ahead of access problems.

Every output reaches a person before anything happens to a patient. What goes undescribed is the threshold that raises a case, how staff override or dismiss a risk signal, and whether any alert triggers outreach on its own.

BB on Model and Technology TransparencyThe approach or the suppliers are named without the version and update discipline behind them. Naming a supplier is the entry to this band both here and on Model Supply Chain Disclosure, which ask different questions of the same disclosure: who receives the data, and what produces the output.
Vendor Published

Cara is ConcertAI's named agentic AI platform. Inside Cadence it aggregates specialty commercial data, runs automated real time quality checks and supplies the predictive signals behind access to start, persistence, hub performance and stockout alerts.

Patient Compass turns pharmacy records into fulfillment and persistence measures, Market Intelligence pairs an AI copilot with claims, hub, support and social determinants data for root cause analysis, and the Patient Access workbench predicts policy to action outcomes after a coverage change. ConcertAI says Cara is trained on curated clinical data. The model families, release identifiers, the training populations behind the commercial predictions and how a model update is announced to customers are not named.

BB on Model Supply Chain DisclosureSubstantial partial disclosure, or a chain that is structurally short: an in house build, a cleared model that cannot be quietly swapped, or a deployment where the transfer does not occur at all. Naming the model provider exits the band below into this one; the axis rises from here on the completeness of the party list and on the terms that govern data once it arrives.
Vendor Published

The model layer is Cara, ConcertAI's proprietary agentic AI platform, which produces the predictive alerts, quality checks and assistant features, so the core is an in house build rather than a licensed outside model. Data arrives from specialty pharmacies, claims sources, hubs and support programs, and those feeds say where patient records originate rather than who processes them. AWS and NVIDIA are named technology partners for ConcertAI as a whole, with no role assigned inside Cadence.

Whether the Market Intelligence copilot or Field AI Assistant calls a model from an outside provider, whether prompts or patient context persist with any supplier, and whether manufacturer data can train future models are left unstated, and no subprocessor list covers the suite.

CC on Clinical and Operational EvidenceNamed customers, or vendor reported percentages with no method, denominator or reference standard. Scale of use is recorded here and is not treated as evidence of benefit.
Vendor Published

Greg Rechtenbach, director of reimbursement at Jazz Pharmaceuticals, says the ability to view, save and share standardized reports keeps his field team aligned and that predictive alerts help it address access problems earlier. The quote names a team and a workflow and gives no measured effect.

ConcertAI's headline figures are 15% better adherence, 5% faster time to fill, a 7% cut in patient churn and persistence extended by 30 days or more, alongside a 3 day cut in time to therapy, a 12% lift in therapy initiation and up to 25% fewer data errors. None of them names a brand, a cohort, a comparison period or a method.

CC on AI Safety and PHI StewardshipGeneral assurances of privacy and security that do not answer the questions artificial intelligence raises: what is retained, what reaches a model, and what happens to it there.
Vendor Published

Patient Compass and Field AI Assistant combine patient level records from specialty pharmacies, hubs, claims and support programs for access and reimbursement work, and field staff follow up in a secure case management tool. Automated quality checks run over incoming feeds, which protects the accuracy of what staff see.

The questions AI raises go unanswered: how long model inputs and outputs are kept, what deidentification applies before data reaches the copilot, whether one manufacturer's patient data can train models used for another, and how a safety or privacy event involving a prediction is investigated and reported. ConcertAI's general privacy policy covers its websites rather than this data.

Regulatory and Compliance
DD on HIPAA and BAA PostureNo statement of status and no privacy document that reaches the product. Both halves are absent at this grade: a service level privacy document on its own lifts a vendor to the band above even where no status is stated. A website privacy notice, including one that says it does not cover customer data, does not reach the product, so a vendor whose only document is that notice and who states no status grades here.
Vendor Published

Patient level views draw on claims, specialty pharmacy and support program records, and field staff work identifiable cases. No statement says whether ConcertAI acts as a business associate, a hub's downstream contractor or a manufacturer's vendor under patient authorization for this data, and the only privacy notice covers ConcertAI's marketing sites and demo inquiries.

The oncology and trial programs from the same parent run under their own participation agreements, which do not reach Cadence. Which workbenches handle protected health information, what a specialty pharmacy or hub may pass to a manufacturer through them, and whether a business associate agreement is offered all sit in the commercial contract.

DD on Security Certifications and Trust CenterControls are asserted with nothing independent behind them, or nothing is published. Read the note before concluding anything: this is the grade most often corrected on a second pass, because assurance material frequently sits on a parent domain or inside an old announcement rather than on the product pages.
Vendor Published

Field reimbursement teams work patient cases in a secure case management tool, and automated real time quality checks screen incoming feeds before data reaches dashboards, which ConcertAI says cuts data errors by up to 25%. That control concerns data quality rather than security assurance. Access is organized by team, with trade users seeing inventory and field staff seeing patient cases, and ConcertAI's privacy policy covers its public websites and demo inquiries.

For a suite holding patient level specialty pharmacy, hub and claims records on behalf of manufacturers, no SOC 2 report, HITRUST or ISO 27001 certificate, penetration test schedule or trust portal is offered. The protections around those views rest on the company's description alone.

CC on FDA and Regulatory StatusNo device claim is made and the product is scoped accordingly. Most administrative and operational products sit here and are not penalized for it, because this axis grades the appropriateness of the positioning rather than possession of a clearance. A stated limit on use, such as research use only or a clause that the product gives no medical advice, beside marketing that sells the product for clinical decisions also sits here, with both quoted, because the buyer has to ask which one governs.
Vendor Published

The suite works on access to treatment that has already been prescribed. Field reimbursement staff see where coverage, affordability or a missing requirement has delayed a patient, trade teams see stockout risk, and brand teams study payer, pharmacy and geography patterns. Suggested next steps go to staff coordinating a case or analyzing the data, never to a clinician choosing therapy.

ConcertAI makes no device claim for Cadence and does not market it for diagnosis, treatment selection or prescribing, which matches what the product does. The positioning is commercial and administrative from end to end, with no stated exclusion or other regime named alongside it.

DD on AI Governance and Bias DisclosureNothing published on how model behavior is governed or tested. Multilingual operation with no subgroup performance sits here when the vendor markets recognition quality as a strength, because a caller the system failed to understand leaves no complaint and no record.
Vendor Published

Benchmarking compares fill rates, abandonment and time to fill across payers, pharmacies, prescribers and regions, and Market Intelligence segments access and adherence trends with social determinants data. Those views can show a brand where some patients wait longer than others between prescription and dispense. They do not show whether the predictive alerts themselves miss more delayed patients, or rank them lower, in one payer mix, region or demographic group than another.

Cadence comes with no subgroup results, fairness method, evaluation material for a manufacturer's review committee or governance framework of its own. A tool that ranks which patients get field outreach first leaves that question with the customer.

CC on AI Liability and RecourseMechanisms exist that let someone challenge an output, such as audit trails, source traceability or review before commit, with nothing standing behind the output and no route for the harmed party.
Vendor Published

Suggestions land in a workbench where field reimbursement staff see the fill, coverage and program data behind a flagged case before acting, and standardized reports let a team save and share the basis for its follow up. That gives staff a way to check an alert against the underlying record. Nothing stands behind the alert itself.

ConcertAI's website terms disclaim accuracy warranties for site materials and cap cumulative liability for the site at $10, a cap that governs the website rather than the product. No commitment to correct a misidentified access barrier, remedy a wrong stockout prediction or answer for a bad prioritization appears outside the suite agreement, and no error rate is given for the predictions.

Integration and Deployment
DD on EHR and Interoperability DepthNo integration evidence. A connector described as available on request grades here until one exists.
Vendor Published

Integration runs to commercial and channel data rather than clinical records. Specialty pharmacy feeds, claims, hub and support program data, social determinants, and shipment and inventory data enter the workbenches, and Specialty Pharmacy Benchmarking pulls feeds from every pharmacy serving a brand. Field AI Assistant coordinates outreach to prescribers, yet no electronic health record connection is named for reading the chart or writing a case update back into it.

CancerLinQ, from the same parent, takes oncology practice records for a different job and is sold separately. For a product whose users are manufacturers' field teams the absence fits the workflow, but none of the channel connections is a named record system integration either.

DD on Deployment Model and Data ResidencyNothing published about where the system runs or where the data rests.
Vendor Published

Cadence Suite reaches users as a ConcertAI application, with field reimbursement, market access, brand and trade teams each working in their own view of the same connected feeds. Trade users see shipments, specialty pharmacy and distributor inventory and channel demand, while field staff see patient level cases. Where the application and those patient records run is never stated.

AWS appears among ConcertAI's company partners without being tied to this product, no hosting model, region or residency commitment is given, and nothing describes how one manufacturer's data is kept apart from another's when several brands draw on shared pharmacy networks. The feed connections describe data moving in, not where it rests once inside.

Commercial
CC on Commercial TransparencyNo price is published and the posture is discoverable: a buyer can establish how the product is sold and what drives the cost before contacting the vendor. Most of the index sits here.
Vendor Published

Manufacturers reach the suite through a ConcertAI demo request and a specialist call, with no subscription price, usage measure or priced starter package. Scope is still easy to size. The workbenches are sold by team, Market Access, Patient Access, Vantage and Brand Insight among them, so a deal can run from one brand's field reimbursement team to a portfolio wide rollout across access, brand and trade groups.

Every deployment needs specialty pharmacy, hub and claims feeds connected, and ConcertAI says full implementation can take as little as 30 days. The unit of charge, minimum number of brands and any data licensing fee sit in the proposal.

BB on Setting and Specialty CoverageCoverage is named with validation behind part of it.
Vendor Published

Specialty pharmaceutical manufacturers are the buyers, across therapeutic areas, with four teams inside them. Field reimbursement and patient support staff work cases stuck before a first fill, market access teams handle payer policy and formulary changes, brand teams compare payer, pharmacy and regional performance, and trade and distribution teams watch shipments and channel demand.

Jazz Pharmaceuticals is the named deployment, using standardized reports and predictive alerts in field reimbursement. ConcertAI cites 30 years of specialty pharmacy data work across more than 80 specialty products, experience that spans the parent's history rather than this suite. Results by therapy area, brand size or support program model have no breakdown.

Alternatives

Alternatives to Cadence Suite

Other products that do the same kind of work as Cadence Suite, and what each one does.

Courier Health gives biopharma teams a shared system for managing patient access to specialty therapies. It connects information from hubs, specialty pharmacies, payers and internal teams so staff can see enrollment progress, authorization barriers, therapy starts and ongoing adherence.

Phluence sells agentic AI to pharmaceutical manufacturers for patient services and commercialization.

Forus, formerly Tandem (renamed in May 2026 with no change in ownership), is a medication access platform that automates the path from prescription to therapy at the point of prescribing.

SureCost sells pharmacy supply software that brings purchasing, inventory and drug shortage forecasting into one workflow, under the Smart Supply name.

HendrenAI builds voice and workflow agents for pharmacies, health systems and pharmaceutical manufacturers.

Plenful automates pharmacy back-office work for health systems, specialty pharmacies and infusion teams, centered on the 340B drug pricing program.

Commercial

Pricing

Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.

Entry Price Pricing Basis BAA Tier Implementation Source
Enterprise quote
ConcertAI sells Cadence Suite to specialty pharmaceutical manufacturers through a demo and an enterprise proposal, with workbenches for field reimbursement, market access, brand analytics and trade and distribution teams, each running on connected pharmacy, hub and claims feeds. Business associate coverage for patient level access workflows, and which workbenches it reaches, is set in the commercial agreement. ConcertAI says the suite can be fully implemented in as little as 30 days. No fee is listed for connecting specialty pharmacy, hub and claims feeds or configuring workbenches. Vendor Published

No subscription price, unit of charge, minimum brand count or priced entry package appears, and a demo is the only route in.